{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:32:37Z","timestamp":1787614357470,"version":"build-2736575974"},"reference-count":105,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>For decades, platinum chemotherapy was the mainstay of treating metastatic urothelial carcinoma (mUC). More recently, checkpoint inhibitors (CPI) were an important addition to the armamentarium capable of inducing durable responses for a minority of patients. Management of mUC has changed significantly with the advent of antibody-drug conjugate (ADC) therapies and fibroblast growth factor receptor inhibitors (FGFRi). Enfortumab vedotin, a Nectin-4 targeting ADC, is now the first line therapy of choice in combination with pembrolizumab. Erdafitinib, a pan FGFR1\u20134 inhibitor, is approved for patients with susceptible FGFR3 alterations. There are multiple other agents in development within both therapeutic classes that hold promise. But most patients will still succumb to their disease, either via primary or secondary resistance. This review looks critically at the approved and pipeline ADC and FGFR-targeting agents of interest in mUC as well as known mechanisms of resistance by which their efficacy is dampened. We propose strategies for overcoming resistance including combination strategies, tumor microenvironment modification, and drug structure modification to maximize efficacy. The progress to date in mUC has been remarkable, but there is still significant work to do in this deadly disease and this review highlights the gap between current available therapeutics and cure that so desperately needs to be closed.<\/jats:p>","DOI":"10.3389\/fonc.2025.1654771","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T05:14:50Z","timestamp":1764652490000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Overcoming resistance in advanced urothelial carcinoma: mechanisms of escape from antibody-drug conjugates and FGFR3 inhibition"],"prefix":"10.3389","volume":"15","author":[{"given":"Brandon","family":"Wummer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Ciuro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahid","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyas S.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram M.","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley C.","family":"Carthon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Asim","family":"Bilen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline T.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-019-02984-4","article-title":"The global burden of urinary bladder cancer: an update","volume":"38","author":"Richters","year":"2020","journal-title":"World J Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"10","author":"Loehrer","year":"1992","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40425-017-0299-1","article-title":"Biomarkers for immunotherapy in bladder cancer: a moving target","volume":"5","author":"Aggen","year":"2017","journal-title":"J ImmunoTherapy Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine\u2013cisplatin in advanced urothelial carcinoma","volume":"389","author":"Heijden","year":"2023","journal-title":"New Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-panTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/cancers11030394","article-title":"Acquired resistance to antibody-drug conjugates","volume":"11","author":"Collins","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4631","DOI":"10.3390\/cancers13184631","article-title":"Generation of antibody-drug conjugate resistant models","volume":"13","author":"Gandullo-Sanchez","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2016-0042","article-title":"A place for precision medicine in bladder cancer: targeting the FGFRs","volume":"12","author":"di Martino","year":"2016","journal-title":"Future Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2018.02.013","article-title":"Prognostic effect of FGFR mutations or gene fusions in patients with metastatic urothelial carcinoma receiving first-line platinum-based chemotherapy: results from a large, single-institution cohort","volume":"5","author":"Necchi","year":"2019","journal-title":"Eur Urol Focus"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat Biotechnol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e118","DOI":"10.1038\/oncsis.2014.32","article-title":"Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancer","volume":"3","author":"Lattanzio","year":"2014","journal-title":"Oncogenesis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cellbio.24.110707.175339","article-title":"The immunoglobulin-like cell adhesion molecule nectin and its associated protein afadin","volume":"24","author":"Takai","year":"2008","journal-title":"Annu Rev Cell Dev Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8365","article-title":"High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer","volume":"15","author":"Zhang","year":"2018","journal-title":"Oncol Lett"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV\u2212201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.7_suppl.238","article-title":"Defining \u201ccisplatin ineligible\u201d patients with metastatic bladder cancer","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4502","article-title":"Exploratory analysis of responders from the phase 3 EV-302 trial of enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la\/mUC)","volume":"43","author":"Gupta","year":"2025","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"102351","DOI":"10.1016\/j.ctrv.2022.102351","article-title":"The evolving panorama of HER2-targeted treatments in metastatic urothelial cancer: A systematic review and future perspectives","volume":"104","author":"Patelli","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-015-9552-6","article-title":"HER2 expression status in diverse cancers: review of results from 37,992 patients","volume":"34","author":"Yan","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c18-00744","article-title":"The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy","volume":"67","author":"Nakada","year":"2019","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1513","article-title":"Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: analysis of the phase ib DS8201-A-U105 study","volume":"30","author":"Hamilton","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01614-x","article-title":"Disitamab vedotin: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02912","article-title":"Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2-positive locally advanced or metastatic urothelial carcinoma: A combined analysis of two phase II clinical trials","volume":"42","author":"Sheng","year":"2024","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"100637","DOI":"10.1016\/j.medj.2025.100637","article-title":"Efficacy and safety of DV in HER2-negative and HER2-low locally advanced or metastatic urothelial carcinoma: Results of a phase 2 study","volume":"6","author":"Yan","year":"2025","journal-title":"Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/oncolo\/oyae304","article-title":"Real-world application of disitamab vedotin (RC48-ADC) in patients with breast cancer with different HER2 expression levels: efficacy and safety analysis","volume":"30","author":"Wang","year":"2024","journal-title":"Oncologist"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1230395","article-title":"Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center's real-world study","volume":"14","author":"Wei","year":"2023","journal-title":"Front Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1233196","article-title":"RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib\/II study (HOPE-03)","volume":"13","author":"Wen","year":"2023","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"TPS4616","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4616","article-title":"Phase 3 study of disitamab vedotin with pembrolizumab vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001)","volume":"42","author":"Galsky","year":"2024","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.073","article-title":"Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)","volume":"7","author":"Mathijssen","year":"2001","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3892\/ol.2023.14114","article-title":"Immunohistochemical expression of TROP\u22122 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer","volume":"26","author":"Abbas","year":"2023","journal-title":"Oncol Lett"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e24206","DOI":"10.1200\/JCO.2018.36.15_suppl.e24206","article-title":"Preclinical efficacy studies of DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd","author":"Okajima D.","year":"2018","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.663","article-title":"Datopotamab deruxtecan (Dato-DXd) in locally advanced\/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study","volume":"43","author":"Meric-Bernstam","year":"2025","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"102720","DOI":"10.1016\/j.ctrv.2024.102720","article-title":"Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan","volume":"125","author":"Heist","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.796","article-title":"Efficacy and safety of sacituzumab tirumotecan monotherapy in patients with advanced urothelial carcinoma who progressed on or after prior anti-cancer therapies: Report from the phase 1\/2 MK-2870\u2013001 study","volume":"43","author":"Ye","year":"2025","journal-title":"J Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-10-0168","article-title":"Roles of fibroblast growth factor receptors in carcinogenesis","volume":"8","author":"Haugsten","year":"2010","journal-title":"Mol Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.003","article-title":"Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial","volume":"35","author":"Siefker-Radtke","year":"2024","journal-title":"Ann Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.clgc.2021.10.004","article-title":"Infigratinib in early-line and salvage therapy for FGFR3-altered metastatic urothelial carcinoma","volume":"20","author":"Lyou","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.794","article-title":"Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF\/FGFR genomic alterations: final results from FIGHT-201","volume":"35","author":"Necchi","year":"2024","journal-title":"Ann Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02303","article-title":"FORT-1: phase II\/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1\/3 mRNA expression","volume":"41","author":"Sternberg","year":"2023","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1200\/JCO.2025.43.5_suppl.662","article-title":"A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1","volume":"43","author":"Iyer","year":"2025","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-CT119","article-title":"Abstract CT119: A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations (trial in progress)","volume":"83","author":"Iyer","year":"2023","journal-title":"Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0862","article-title":"Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments","volume":"14","author":"Loganzo","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1557","article-title":"Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab","volume":"11","author":"Filho","year":"2021","journal-title":"Cancer Discov"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv577","article-title":"Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial","volume":"27","author":"Gebhart","year":"2016","journal-title":"Ann Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Klumper","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PloS Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8132","article-title":"Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use","volume":"7","author":"Patani","year":"2016","journal-title":"Oncotarget"},{"key":"B63","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/antib9030032","article-title":"Improving receptor-mediated intracellular access and accumulation of antibody therapeutics-the tale of HER2","volume":"9","author":"Leyton","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"B64","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/ph14070674","article-title":"Impact of endocytosis mechanisms for the receptors targeted by the currently approved antibody-drug conjugates (ADCs)-A necessity for future ADC research and development","volume":"14","author":"Hammood","year":"2021","journal-title":"Pharm (Basel)"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S135571","article-title":"Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates","volume":"11","author":"Kalim","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0403","article-title":"Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1)","volume":"17","author":"Sung","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-20-0222","article-title":"The role of specific ATP-binding cassette transporters in the acquired resistance to pyrrolobenzodiazepine dimer-containing antibody-drug conjugates","volume":"19","author":"Corbett","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30870","article-title":"DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance","volume":"141","author":"Takegawa","year":"2017","journal-title":"Int J Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.690","article-title":"Mechanisms and strategies to overcome resistance to enfortumab vedotin in bladder cancer","volume":"42","author":"Chang","year":"2024","journal-title":"J Clin Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-4792-0","article-title":"Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy","volume":"171","author":"Jain","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"B72","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00280-022-04459-7","article-title":"An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next","volume":"90","author":"D'Angelo","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-1398","article-title":"Adipocyte precursor-derived NRG1 promotes resistance to FGFR inhibition in urothelial carcinoma","volume":"84","author":"Hosni","year":"2024","journal-title":"Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1186\/s12885-022-09478-4","article-title":"Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer","volume":"22","author":"Weickhardt","year":"2022","journal-title":"BMC Cancer"},{"key":"B75","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10238-025-01655-6","article-title":"Mechanism of action and future perspectives of ADCs in combination with immune checkpoint inhibitors for solid tumors","volume":"25","author":"Lv","year":"2025","journal-title":"Clin Exp Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1936494","article-title":"Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics","volume":"21","author":"Saini","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e1565859","DOI":"10.1080\/2162402X.2019.1565859","article-title":"Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells","volume":"8","author":"Bauzon","year":"2019","journal-title":"Oncoimmunology"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2854","article-title":"Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies","volume":"77","author":"Rios-Doria","year":"2017","journal-title":"Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-1065","article-title":"FGFR3 alterations in bladder cancer stimulate serine synthesis to induce immune-inert macrophages that suppress T-cell recruitment and activation","volume":"83","author":"Ouyang","year":"2023","journal-title":"Cancer Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O'Donnell","year":"2023","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN guidelines(R) insights: bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.010","article-title":"Avelumab + sacituzumab govitecan (SG) vs avelumab monotherapy as first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC): Interim analysis from the JAVELIN Bladder Medley phase 2 trial","author":"Hoffman-Censits","year":"2025","journal-title":"J Clin Oncol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"TPS4627","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4627","article-title":"SMART: A phase II study of sacituzumab govitecan (SG) with or without atezolizumab immunotherapy in rare genitourinary (GU) tumors such as small cell, adenocarcinoma, and squamous cell bladder\/urinary tract cancer, renal medullary carcinoma (RMC) and penile cancer","volume":"42","author":"Kydd","year":"2024","journal-title":"J Clin Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.3114","article-title":"The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma","volume":"35","author":"McGregor","year":"2024","journal-title":"Ann Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"TPS4618","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS4618","article-title":"Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment na\u00efve UC (DAD-IO)","volume":"42","author":"McGregor","year":"2024","journal-title":"J Clin Oncol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41591-021-01317-6","article-title":"An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer","volume":"27","author":"Powles","year":"2021","journal-title":"Nat Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4504","article-title":"Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study","volume":"41","author":"Siefker-Radtke","year":"2023","journal-title":"J Clin Oncol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.7150\/jca.40531","article-title":"FGF\/FGFR signaling pathway involved resistance in various cancer types","volume":"11","author":"Zhou","year":"2020","journal-title":"J Cancer"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0415","article-title":"PI3K inhibitors synergize with FGFR inhibitors to enhance antitumor responses in FGFR2(mutant) endometrial cancers","volume":"16","author":"Packer","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.2c00947","article-title":"Targeted nanodrugs to destroy the tumor extracellular matrix barrier for improving drug delivery and cancer therapeutic efficacy","volume":"20","author":"Chen","year":"2023","journal-title":"Mol Pharm"},{"key":"B92","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0938","article-title":"A phase I study of the P-glycoprotein antagonist tariquidar in combination with vinorelbine","volume":"15","author":"Abraham","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2845-1","article-title":"Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine, or docetaxel in children and adolescents with refractory solid tumors","volume":"76","author":"Fox","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0013","article-title":"Overcoming resistance to anti-nectin-4 antibody-drug conjugate","volume":"21","author":"Cabaud","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.05.010","article-title":"A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy","volume":"35","author":"Li","year":"2019","journal-title":"Cancer Cell"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.589","article-title":"Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers","volume":"33","author":"Jhaveri","year":"2022","journal-title":"Ann Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-LB448","article-title":"VBC103: An innovative Trop2\/Nectin4 targeted bispecific antibody drug conjugate (ADC) in bladder urothelial carcinoma (UC), triple-negative breast cancer (TNBC) and beyond","volume":"84","author":"Wang","year":"2024","journal-title":"Cancer Res"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.5_suppl.TPS898","article-title":"A phase 2\/3 study of bicycle toxin conjugate zelenectide pevedotin (BT8009) targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer (la\/mUC) (Duravelo-2)","volume":"43","author":"Loriot","year":"2025","journal-title":"J Clin Oncol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"e455","DOI":"10.1002\/mco2.455","article-title":"Targeted therapies in bladder cancer: signaling pathways, applications, and challenges","volume":"4","author":"Peng","year":"2020","journal-title":"MedComm"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/ph11020032","article-title":"Antibody-drug conjugates for cancer therapy: chemistry to clinical implications","volume":"11","author":"Dan","year":"2018","journal-title":"Pharm (Basel)"},{"key":"B103","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.3390\/cancers16132420","article-title":"Antibody-drug conjugates in urothelial cancer: from scientific rationale to clinical development","volume":"16","author":"Kwon","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B104","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat Commun"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1\u20134 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: A phase I dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1654771\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T05:14:51Z","timestamp":1764652491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1654771\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":105,"alternative-id":["10.3389\/fonc.2025.1654771"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1654771","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"article-number":"1654771"}}